Trial Profile

A Phase I Dose-escalation Trial of TG6050 Administered by Intravenous Infusion in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TG 6050 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man
Acronyms Delivir
Sponsors Transgene

Most Recent Events

09 Jul 2025 Status changed from recruiting to discontinued. Reason the study was stopped: Sponsor decision not related to safety.
03 Dec 2024 Planned End Date changed from 31 Mar 2025 to 31 Oct 2025.
03 Dec 2024 Planned primary completion date changed from 30 Oct 2024 to 30 Apr 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com